Selective sensitivity of Ph-like B-cell acute lymphoblastic leukemia to BRG1 inhibition identifies a therapeutic vulnerability
V S S Abhinav Ayyadevara, Ria Perencsik, Shreya Patil, Shikha Gaur, Ashley Paik, Monika Toma, Gerald Wertheim, Huimin Geng, Tomasz Skorski, Srividya Swaminathan, Christian Hurtz · 2026
Read Selective sensitivity of Ph-like B-cell acute lymphoblastic leukemia to BRG1 inhibition identifies a therapeutic vulnerability by V S S Abhinav Ayyadevara, Ria Perencsik, Shreya Patil, Shikha Gaur, Ashley Paik, Monika Toma, Gerald Wertheim, Huimin Geng, Tomasz Skorski, Srividya Swaminathan, Christian Hurtz (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13421310.txt.
Description
Abhinav Ayyadevara and ten colleagues write to the editor in 2026 about a drug target in Ph-like B-cell acute lymphoblastic leukaemia. This high-risk subtype relapses often. Three-year survival sits near 65 percent. They focus on BRG1, a motor protein of the SWI/SNF chromatin complex that early B cells need.
In solid tumours, losing a related gene makes cancers depend on BRG1's partner protein, yet blood cancers show the reverse pattern: they depend on BRG1 itself. The team's experiments found this leukaemia subtype selectively sensitive to BRG1 blockade. They present that sensitivity as a therapeutic vulnerability worth exploiting, since options after relapse remain poor.
Catalog record
| CREATOR | V S S Abhinav Ayyadevara, Ria Perencsik, Shreya Patil, Shikha Gaur, Ashley Paik, Monika Toma, Gerald Wertheim, Huimin Geng, Tomasz Skorski, Srividya Swaminathan, Christian Hurtz |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 16625 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |